WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 407850

CAS#: 2412149-32-5 (TFA)

Description: PSMA-11, also known as DKFZ-​PSMA-​11, HBED-CC-PSMA or Psma-hbed-CC, is a ligand to make gallium Ga 68-labeled PSMA-11, which has potential use as a tracer for PSMA-expressing tumors during positron emission tomography (PET). Upon intravenous administration of gallium Ga 68-labeled PSMA-11, the Glu-urea-Lys(Ahx) moiety targets and binds to PSMA-expressing tumor cells. Upon internalization, PSMA-expressing tumor cells can be detected during PET imaging. PSMA, a tumor-associated antigen and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells

Chemical Structure

CAS# 2412149-32-5 (TFA)

Theoretical Analysis

MedKoo Cat#: 407850
Name: PSMA-11 TFA
CAS#: 2412149-32-5 (TFA)
Chemical Formula: C48H64F6N6O21
Exact Mass: 946.4171
Molecular Weight: 1175.0514
Elemental Analysis: C, 49.06; H, 5.49; F, 9.70; N, 7.15; O, 28.59

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 2412149-32-5 (TFA)   1366302-52-4 (free base)    

Synonym: DKFZ-​PSMA-​11; Psma-hbed-CC; PSMA-11; PSMA11; PSMA 11; HBED-CC-PSMA; PSMA-11 TFA; Psma-hbed-CC

IUPAC/Chemical Name: (3S,7S)-22-(3-(((2-((5-(2-carboxyethyl)-2-hydroxybenzyl)(carboxymethyl)amino)ethyl)(carboxymethyl)amino)methyl)-4-hydroxyphenyl)-5,13,20-trioxo-4,6,12,19-tetraazadocosane-1,3,7-tricarboxylic acid compound with 2,2,2-trifluoroacetic acid (1:2)


InChi Code: InChI=1S/C44H62N6O17.2C2HF3O2/c51-34-13-8-28(22-30(34)24-49(26-40(59)60)20-21-50(27-41(61)62)25-31-23-29(9-14-35(31)52)11-16-38(55)56)10-15-37(54)46-18-4-1-2-7-36(53)45-19-5-3-6-32(42(63)64)47-44(67)48-33(43(65)66)12-17-39(57)58;2*3-2(4,5)1(6)7/h8-9,13-14,22-23,32-33,51-52H,1-7,10-12,15-21,24-27H2,(H,45,53)(H,46,54)(H,55,56)(H,57,58)(H,59,60)(H,61,62)(H,63,64)(H,65,66)(H2,47,48,67);2*(H,6,7)/t32-,33-;;/m0../s1


Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in water

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 1175.0514 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Verma P, Malhotra G, Meshram V, Chandak A, Sonavane S, Lila AR, Bandgar TR, Asopa RV. Prostate-Specific Membrane Antigen Expression in Patients With Differentiated Thyroid Cancer With Thyroglobulin Elevation and Negative Iodine Scintigraphy Using 68Ga-PSMA-HBED-CC PET/CT. Clin Nucl Med. 2021 Aug 1;46(8):e406-e409. doi: 10.1097/RLU.0000000000003655. PMID: 33883490.

2: Guglielmo P, Gasparro D, Scarlattei M, Baldari G, Bola S, Migliari S, Sammartano A, Maestroni U, Ruffini L. [68Ga]Ga-PSMA-HBED-CC PET/CT demonstrates to be superior to ceCT in detecting early treatment response in metastatic clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2021 Mar 22. doi: 10.1007/s00259-021-05250-1. Epub ahead of print. PMID: 33754194.

3: Malhotra G, Aute PP, Awasare S, Asopa RV. 68Ga-PSMA-HBED-CC PET/CT Findings in a Patient of Polyostotic Fibrous Dysplasia. Clin Nucl Med. 2021 Jul 1;46(7):e349-e352. doi: 10.1097/RLU.0000000000003492. PMID: 33417342.

4: Yip JWL, Hilliar L, Le K, Loh H, Mansberg R. 68Ga-Prostate-Specific Membrane Antigen Solitary Base of Skull Prostate Adenocarcinoma Metastasis. Clin Nucl Med. 2021 Jan;46(1):63-65. doi: 10.1097/RLU.0000000000003390. PMID: 33181755.

5: Grubmüller B, Jahrreiss V, Huebner N, Mitterhauser M, Stangl-Kremser J, Grubmüller KH, Baltzer P, Hacker M, Goldner G, Shariat SF, Rasul S. Differential impact of radiation therapy after radical prostatectomy on recurrence patterns: an assessment using [68Ga]Ga-PSMA ligand PET/CT(MRI). Prostate Cancer Prostatic Dis. 2021 Jun;24(2):439-447. doi: 10.1038/s41391-020-00294-0. Epub 2020 Sep 29. PMID: 32994534.

6: Golan H, Esa M, Moshkoviz K, Feldhaim A, Hoch B, Shalom E. Enhancing capacity and synthesis of [68Ga]68-Ga-PSMA-HBED-CC with the lyophilized ready-to-use kit for nuclear pharmacy applications. Nucl Med Commun. 2020 Sep;41(9):986-990. doi: 10.1097/MNM.0000000000001232. PMID: 32796488.

7: Sørensen MA, Andersen VL, Hendel HW, Vriamont C, Warnier C, Masset J, Huynh THV. Automated synthesis of 68 Ga/177 Lu-PSMA on the Trasis miniAllinOne. J Labelled Comp Radiopharm. 2020 Jun 30;63(8):393-403. doi: 10.1002/jlcr.3846. Epub 2020 Jun 1. PMID: 32374450.

8: Wong VCK, Yip JWL, Stevanovic A, Le K, Mansberg R. 68Ga-Prostate-Specific Membrane Antigen Uptake in Dissecting Abdominal Aortic Aneurysm. Clin Nucl Med. 2020 Jun;45(6):455-458. doi: 10.1097/RLU.0000000000002972. PMID: 32149812.

9: Sood A, Vadi SK, Kumar R, Singh H, Mittal BR. Incidental Detection of Hypothyroidism on 68Ga-PSMA-HBED-CC PET/CT Imaging. Clin Nucl Med. 2020 Apr;45(4):e217-e218. doi: 10.1097/RLU.0000000000002965. PMID: 32108699.

10: van Boxtel W, Lütje S, van Engen-van Grunsven ICH, Verhaegh GW, Schalken JA, Jonker MA, Nagarajah J, Gotthardt M, van Herpen CML. 68Ga-PSMA-HBED- CC PET/CT imaging for adenoid cystic carcinoma and salivary duct carcinoma: a phase 2 imaging study. Theranostics. 2020 Jan 12;10(5):2273-2283. doi: 10.7150/thno.38501. PMID: 32089741; PMCID: PMC7019174.

11: Sakthivel P, Thakar A, Prashanth A, Bhalla AS, Kakkar A, Sikka K, Singh CA, Kumar R, Sharma SC, Kumar R. Prostate-Specific Membrane Antigen Expression in Primary Juvenile Nasal Angiofibroma-A Pilot Study. Clin Nucl Med. 2020 Mar;45(3):195-199. doi: 10.1097/RLU.0000000000002928. PMID: 31977481.

12: Wong VCK, Shen L, Nasser E, Adams DN, Mansberg R. 68Ga-Prostate-Specific Membrane Antigen Uptake in Cerebral Tuberculosis. Clin Nucl Med. 2020 Mar;45(3):238-240. doi: 10.1097/RLU.0000000000002910. PMID: 31977467.

13: Pollard JH, Raman C, Zakharia Y, Tracy CR, Nepple KG, Ginader T, Breheny P, Sunderland JJ. Quantitative Test-Retest Measurement of 68Ga-PSMA- HBED-CC in Tumor and Normal Tissue. J Nucl Med. 2020 Aug;61(8):1145-1152. doi: 10.2967/jnumed.119.236083. Epub 2019 Dec 5. PMID: 31806776.

14: Yadav MP, Ballal S, Bal C, Sahoo RK, Damle NA, Tripathi M, Seth A. Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration- Resistant Prostate Cancer Patients. Clin Nucl Med. 2020 Jan;45(1):19-31. doi: 10.1097/RLU.0000000000002833. PMID: 31789908.

15: Parihar AS, Sood A, Mittal BR, Kumar R, Singh H, Dhatt SS. 68Ga-PSMA-HBED-CC PET/CT and 18F-FDG PET/CT in Ewing Sarcoma. Clin Nucl Med. 2020 Jan;45(1):e57-e58. doi: 10.1097/RLU.0000000000002764. PMID: 31524682.

16: Schmidkonz C, Cordes M, Goetz TI, Prante O, Kuwert T, Ritt P, Uder M, Wullich B, Goebell P, Bäuerle T. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients. Ann Nucl Med. 2019 Oct;33(10):766-775. doi: 10.1007/s12149-019-01387-0. Epub 2019 Jul 23. PMID: 31338731.

17: Wo S, Matesan MC. 18F-Fluciclovine Uptake in Celiac Ganglia: A Pitfall in Prostate Cancer PET Imaging. Clin Nucl Med. 2019 Sep;44(9):743-745. doi: 10.1097/RLU.0000000000002693. PMID: 31283598.

18: Sheng K, Le K, Bui C, Mansberg R. Incidental Detection of Splenic Hemangioma on 68Ga-PSMA PET/CT. Clin Nucl Med. 2019 Oct;44(10):821-823. doi: 10.1097/RLU.0000000000002662. PMID: 31162264.

19: McCarthy M, Francis R, Tang C, Watts J, Campbell A. A Multicenter Prospective Clinical Trial of 68Gallium PSMA HBED-CC PET-CT Restaging in Biochemically Relapsed Prostate Carcinoma: Oligometastatic Rate and Distribution Compared With Standard Imaging. Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):801-808. doi: 10.1016/j.ijrobp.2019.03.014. Epub 2019 Mar 16. PMID: 30890448.

20: Verma P, Malhotra G, Goel A, Rakshit S, Chandak A, Chedda R, Banerjee S, Asopa RV. Differential Uptake of 68Ga-PSMA-HBED-CC (PSMA-11) in Low-Grade Versus High-Grade Gliomas in Treatment-Naive Patients. Clin Nucl Med. 2019 May;44(5):e318-e322. doi: 10.1097/RLU.0000000000002520. PMID: 30829867.